文献速递呼吸道感染

成人社区获得性肺炎经验性抗生素治疗:系统综述与网络荟萃分析

Empiric antibiotics for community-acquired pneumonia in adult patients: a systematic review and a network meta-analysis.
PubMed 文献 · Thorax · 2021-03-15

该网络荟萃分析纳入27项RCT,评估住院成人CAP患者经验性抗生素的治愈率与死亡率。治愈率方面,头孢洛林和哌拉西林概率最高;死亡率方面,头孢曲松联合左氧氟沙星、厄他培南及阿米卡星联合克拉霉素概率最高。证据确定性均为中等。

要点

  • 治愈率概率最高的经验性方案为头孢洛林600mg每日两次和哌拉西林2000mg每日两次。
  • 死亡率概率最高的方案为头孢曲松2000mg每日一次联合左氧氟沙星500mg每日两次、厄他培南1000mg每日两次、阿米卡星250mg每日两次联合克拉霉素500mg每日两次。
  • 各结果证据确定性均为中等,需RCT直接比较治愈与死亡率最优方案。

核心结论

  • 治愈率方面,头孢洛林和哌拉西林概率最高。
  • 死亡率方面,头孢曲松联合左氧氟沙星、厄他培南及阿米卡星联合克拉霉素概率最高。
  • 证据确定性均为中等。

研究设计与样本

  • 纳入标准:>16岁住院CAP成人,随机至至少两种经验性抗生素,报告治愈率,英文或西班牙文。

主要发现

  • 治愈率分析构建两个网络,头孢洛林600mg每日两次和哌拉西林2000mg每日两次概率最高。
  • 死亡率分析构建三个网络,头孢曲松2000mg每日一次联合左氧氟沙星500mg每日两次、厄他培南1000mg每日两次、阿米卡星250mg每日两次联合克拉霉素500mg每日两次概率最高。
  • 超过四分之一研究偏倚风险低,无研究在所有领域高偏倚风险;系统综述质量中等。

关键数值与推荐

  • 治愈率最优概率:头孢洛林600mg每日两次;哌拉西林2000mg每日两次。
  • 死亡率最优概率:头孢曲松2000mg每日一次联合左氧氟沙星500mg每日两次;厄他培南1000mg每日两次;阿米卡星250mg每日两次联合克拉霉素500mg每日两次。
  • 各结果证据确定性均为中等。

临床怎么用

  • 住院CAP经验性选药可参考治愈率或死亡率最优概率方案,但需结合当地耐药与患者情况。
  • 证据确定性中等,临床决策应个体化并关注直接比较研究。

局限性

  • 仅纳入英文或西班牙文文献。
  • 排除方案不明确及仅摘要或信件格式发表的研究。
  • 需RCT直接比较治愈与死亡率最优方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The main aim of this network meta-analysis is to identify the empiric antibiotic (Em-ATB) with the highest probability of being the best (HPBB) in terms of (1) cure rate and (2) mortality rate in hospitalised patients with community acquired pneumonia (CAP) . METHOD: Inclusion criteria: (1) adult patients (>16 years old) diagnosed with CAP that required hospitalisation; (2) randomised to at least two different Em-ATBs, (3) that report cure rate and (4) are written in English or Spanish. EXCLUSION CRITERIA: (1) ambiguous antibiotics protocol and (2) published exclusively in abstract or letter format. DATA SOURCES: Medline, Embase, Cochrane and citation reviews from 1 January 2000 to 31 December 2018. Risk of bias: Cochrane's tool. Quality of the systematic review (SR): A MeaSurement Tool to Assess systematic Reviews-2. Certainity of the evidence: Grading of Recommendations Assessment, Development and Evaluation. STATISTICAL ANALYSES: frequentist method performed with the 'netmeta' library, R package. RESULTS: 27 randomised controlled trials (RCTs) from the initial 41 307 screened citations were included. Regarding the risk of bias, more than one quarter of the studies presented low risk and no study presented high risk in all domains. The SR quality is moderate. For cure, two networks were constructed. Thus, two Em-ATBs have the HPBB: cetaroline 600 mg (two times a day) and piperacillin 2000 mg (two times a day). For mortality, three networks were constructed. Thus, three Em-ATBs have the HPBB: ceftriaxone 2000 mg (once a day) plus levofloxacin 500 (two times a day), ertapenem 1000 mg (two times a day) and amikacin 250 mg (two times a day) plus clarithromycin 500 mg (two times a day). The certainity of evidence for each results is moderate. CONCLUSION: For cure rate, ceftaroline and piperaciline are the options with the HPBB. However, for mortality rate, the options are ceftriaxone plus levofloxacin, ertapenem and amikacin plus clarithromycin. It seems necessary to conduct an RCT that compares treatments with the HPBB for each event (cure or mortality) (CRD42017060692).

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Montes-Andujar L, Tinoco E, Baez-Pravia O, et al. Empiric antibiotics for community-acquired pneumonia in adult patients: a systematic review and a network meta-analysis. Thorax. 2021. PMID: 33723019. doi:10.1136/thoraxjnl-2019-214054

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。